Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 732 in Thyroid Eye Disease (Phase 1/2, Japan)
jRCT2031260165Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of AMG 732 in Graves Orbitopathy (GO) (4 arms), sponsored by Amgen. Primary endpoint: Change from baseline in proptosis in the study eye. Started May 2024; status: active, not recruiting.
02
Drugs
AMG 732
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2031260165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260165.